{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T21:53:02Z","timestamp":1781041982713,"version":"3.54.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,9,2]],"date-time":"2012-09-02T00:00:00Z","timestamp":1346544000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1007\/s00280-012-1946-3","type":"journal-article","created":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T21:10:08Z","timestamp":1346533808000},"page":"707-716","source":"Crossref","is-referenced-by-count":30,"title":["Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors"],"prefix":"10.1007","volume":"70","author":[{"given":"Song","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu-Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Quan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Fang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Long","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,9,2]]},"reference":[{"key":"1946_CR1","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947\u2013957","journal-title":"N Engl J Med"},{"key":"1946_CR2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.drup.2007.03.003","volume":"10","author":"G Tortora","year":"2007","unstructured":"Tortora G, Bianco R, Daniele G, Ciardiello F, McCubrey JA, Ricciardi MR, Ciuffreda L, Cognetti F, Tafuri A, Milella M (2007) Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resist Updat 10:81\u2013100","journal-title":"Drug Resist Updat"},{"key":"1946_CR3","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1093\/carcin\/bgh226","volume":"25","author":"BR Balsara","year":"2004","unstructured":"Balsara BR, Pei J, Mitsuuchi Y, Page R, Klein-Szanto A, Wang H, Unger M, Testa JR (2004) Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 25:2053\u20132059","journal-title":"Carcinogenesis"},{"key":"1946_CR4","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1158\/1078-0432.CCR-06-0764","volume":"12","author":"KW Yee","year":"2006","unstructured":"Yee KW, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, Thomas D, Wierda W, Apostolidou E, Albitar M, O\u2019Brien S, Andreeff M, Giles FJ (2006) Phase I\/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 12:5165\u20135173","journal-title":"Clin Cancer Res"},{"key":"1946_CR5","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1101\/gad.887201","volume":"15","author":"AC Gingras","year":"2001","unstructured":"Gingras AC, Raught B, Sonenberg N (2001) Regulation of translation initiation by FRAP\/mTOR. Genes Dev 15:807\u2013826","journal-title":"Genes Dev"},{"key":"1946_CR6","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/00001813-200606000-00001","volume":"17","author":"P Smolewski","year":"2006","unstructured":"Smolewski P (2006) Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs 17:487\u2013494","journal-title":"Anticancer Drugs"},{"key":"1946_CR7","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/sj.bjc.6604269","volume":"98","author":"R Bianco","year":"2008","unstructured":"Bianco R, Garofalo S, Rosa R, Damiano V, Gelardi T, Daniele G, Marciano R, Ciardiello F, Tortora G (2008) Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer 98:923\u2013930","journal-title":"Br J Cancer"},{"key":"1946_CR8","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1093\/jnci\/86.20.1517","volume":"86","author":"TC Chou","year":"1994","unstructured":"Chou TC, Motzer RJ, Tong Y, Bosl GJ (1994) Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 86:1517\u20131524","journal-title":"J Natl Cancer Inst"},{"key":"1946_CR9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/sj.leu.2404471","volume":"21","author":"T Haritunians","year":"2007","unstructured":"Haritunians T, Mori A, O\u2019Kelly J, Luong QT, Giles FJ, Koeffler HP (2007) Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 21:333\u2013339","journal-title":"Leukemia"},{"key":"1946_CR10","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/1078-0432.CCR-06-0833","volume":"12","author":"C Bianco","year":"2006","unstructured":"Bianco C, Giovannetti E, Ciardiello F, Mey V, Nannizzi S, Tortora G, Troiani T, Pasqualetti F, Eckhardt G, de Liguoro M, Ricciardi S, Del Tacca M, Raben D, Cionini L, Danesi R (2006) Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer. Clin Cancer Res 12:7099\u20137107","journal-title":"Clin Cancer Res"},{"key":"1946_CR11","doi-asserted-by":"crossref","first-page":"6487","DOI":"10.1158\/1078-0432.CCR-04-0870","volume":"10","author":"P Matar","year":"2004","unstructured":"Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzman M, Rodriguez S, Arribas J, Palacios J, Baselga J (2004) Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res 10:6487\u20136501","journal-title":"Clin Cancer Res"},{"key":"1946_CR12","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/jnci\/dji238","volume":"97","author":"T Mukohara","year":"2005","unstructured":"Mukohara T, Engelman JA, Hanna NH, Yeap BY, Kobayashi S, Lindeman N, Halmos B, Pearlberg J, Tsuchihashi Z, Cantley LC, Tenen DG, Johnson BE, Janne PA (2005) Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 97:1185\u20131194","journal-title":"J Natl Cancer Inst"},{"key":"1946_CR13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/ijc.20985","volume":"116","author":"F Koizumi","year":"2005","unstructured":"Koizumi F, Shimoyama T, Taguchi F, Saijo N, Nishio K (2005) Establishment of a human non-small cell lung cancer cell line resistant to gefitinib. Int J Cancer 116:36\u201344","journal-title":"Int J Cancer"},{"key":"1946_CR14","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1200\/JCO.2005.02.840","volume":"23","author":"RS Herbst","year":"2005","unstructured":"Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892\u20135899","journal-title":"J Clin Oncol"},{"key":"1946_CR15","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1200\/JCO.2004.08.001","volume":"22","author":"G Giaccone","year":"2004","unstructured":"Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial\u2014INTACT 1. J Clin Oncol 22:777\u2013784","journal-title":"J Clin Oncol"},{"key":"1946_CR16","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2004.07.215","volume":"22","author":"RS Herbst","year":"2004","unstructured":"Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial\u2013INTACT 2. J Clin Oncol 22:785\u2013794","journal-title":"J Clin Oncol"},{"key":"1946_CR17","doi-asserted-by":"crossref","unstructured":"Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, Milanowski J, Karnicka-Mlodkowski H, Pesek M, Serwatowski P et al (2007) Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25:1545\u20131552","DOI":"10.1200\/JCO.2005.05.1474"},{"key":"1946_CR18","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1158\/1078-0432.CCR-06-2923","volume":"13","author":"T Li","year":"2007","unstructured":"Li T, Ling YH, Goldman ID, Perez-Soler R (2007) Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res 13:3413\u20133422","journal-title":"Clin Cancer Res"},{"key":"1946_CR19","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1158\/1535-7163.MCT-06-0166","volume":"5","author":"E Buck","year":"2006","unstructured":"Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, Haley JD, Iwata KK, Gibson NW, Griffin G (2006) Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 5:2676\u20132684","journal-title":"Mol Cancer Ther"},{"key":"1946_CR20","doi-asserted-by":"crossref","first-page":"s4628","DOI":"10.1158\/1078-0432.CCR-07-0717","volume":"13","author":"BE Johnson","year":"2007","unstructured":"Johnson BE, Jackman D, Janne PA (2007) Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer. Clin Cancer Res 13:s4628\u2013s4631","journal-title":"Clin Cancer Res"},{"key":"1946_CR21","doi-asserted-by":"crossref","first-page":"7409","DOI":"10.1158\/0008-5472.CAN-08-1522","volume":"68","author":"X Wang","year":"2008","unstructured":"Wang X, Yue P, Kim YA, Fu H, Khuri FR, Sun SY (2008) Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR\/raptor inhibition-initiated, mTOR\/rictor-independent Akt activation. Cancer Res 68:7409\u20137418","journal-title":"Cancer Res"},{"key":"1946_CR22","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","volume":"22","author":"DD Sarbassov","year":"2006","unstructured":"Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB. Mol Cell 22:159\u2013168","journal-title":"Mol Cell"},{"key":"1946_CR23","first-page":"4931","volume":"57","author":"SY Sun","year":"1997","unstructured":"Sun SY, Yue P, Dawson MI, Shroot B, Michel S, Lamph WW, Heyman RA, Teng M, Chandraratna RA, Shudo K, Hong WK, Lotan R (1997) Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells. Cancer Res 57:4931\u20134939","journal-title":"Cancer Res"},{"key":"1946_CR24","doi-asserted-by":"crossref","first-page":"11300","DOI":"10.1158\/0008-5472.CAN-07-0702","volume":"67","author":"ME Legrier","year":"2007","unstructured":"Legrier ME, Yang CP, Yan HG, Lopez-Barcons L, Keller SM, Perez-Soler R, Horwitz SB, McDaid HM (2007) Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression. Cancer Res 67:11300\u201311308","journal-title":"Cancer Res"},{"key":"1946_CR25","first-page":"3065","volume":"118","author":"A Carracedo","year":"2008","unstructured":"Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118:3065\u20133074","journal-title":"J Clin Invest"},{"issue":"15 suppl","key":"1946_CR26","doi-asserted-by":"crossref","first-page":"7524","DOI":"10.1200\/jco.2010.28.15_suppl.7524","volume":"28","author":"NB Leighl","year":"2010","unstructured":"Leighl NB, Soria J, Bennouna J et al (2010) Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 28(15 suppl):7524","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-012-1946-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-012-1946-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-012-1946-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T10:11:23Z","timestamp":1559038283000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-012-1946-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,2]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["1946"],"URL":"https:\/\/doi.org\/10.1007\/s00280-012-1946-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,2]]}}}